This trial is testing the effects of AZD5363 on patients with cancer that has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth.
1 Primary · 2 Secondary · Reporting Duration: Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration
35 Total Participants · 1 Treatment Group
Primary Treatment: Capivasertib · No Placebo Group · Phase 2
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: